Veppanu (vepdegestrant) becomes the first PROTAC drug to reach market, marking a significant milestone for the novel drug class. Despite the approval, Arvinas and partner Pfizer are still searching for a commercialization partner to sell the breast cancer treatment.

Axsome secured a much-needed label expansion for Auvelity, making it the first non-antipsychotic drug approved to treat agitation in Alzheimer's disease patients. The approval provides a new treatment option in a therapeutic area historically dominated by antipsychotic medications.

An FDA advisory committee recommended approval of capivasertib for prostate cancer treatment, providing positive momentum for the drug candidate. The panel's endorsement increases the likelihood of full regulatory approval in this indication.

Summit's decision to conduct an interim analysis of its closely watched ivonescimab trial backfired, creating a setback characterized as self-inflicted. An FDA committee also sided against AstraZeneca's camizestrant breast cancer medicine, while Esperion announced a take-private deal.

Newron's Phase III schizophrenia trial for evenamide has been placed on enrollment pause following a patient death. The FDA-mandated hold creates uncertainty for the late-stage program's timeline and prospects.

Despite missing its primary endpoint, Corcept's ALS drug candidate showed sustained benefit over two years of treatment. The mixed results present a complex regulatory and commercial path forward for the company.

Strong international performance from Mounjaro drove Lilly's impressive quarterly results, prompting the company to raise both profit and revenue guidance for the year. Attention now shifts to the commercial launch of Foundayo and continued obesity franchise momentum.

Teva completed its largest acquisition in a decade with the $700 million purchase of Emalex and its experimental Tourette syndrome drug. Analysts view the deal favorably given the synergies with Teva's existing neurology business.

Quarterly earnings revealed divergent trajectories among major biopharma companies, with Biogen exceeding expectations on strength from Leqembi and Skyclarys. Investors remain cautious about Bristol Myers and Regeneron's pipelines, awaiting clearer evidence of future growth drivers.

Avalyn Pharma raised $300 million in its initial public offering to develop inhalable versions of existing pulmonary fibrosis therapies. The company is targeting both idiopathic and progressive forms of the disease with its reformulation approach.

Iterative Health secured $77 million in Series C funding to advance its AI-powered clinical research network technology. The investment reflects growing investor confidence in artificial intelligence applications for improving clinical trial operations.